XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today reported the results of its Rotigotine transdermal (“TDS”) patch human skin cadaver study and dissolution data. The company’s Rotigotine patch is based on the TDS platform technology developed by Vektor Pharma TF GmbH, its wholly owned German subsidiary. Further to its product update on Oct. 11, 2022, XPhyto announced excellent results from its recent Rotigotine TDS human cadaver study, which compared drug absorption between the company’s optimized new formula and the name brand product. “As our lead product, we are extremely pleased with these results. They have exceeded our expectations,” said XPhyto CEO and Director Hugh Rogers. “We are confident that our Rotigotine patch is fully optimized and ready for further human clinical evaluation. This is a major milestone in the pathway to product commercialization.”
To view the full press release, visit https://ibn.fm/c5fGk
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.